Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 37 - Drugs for immunological or allergic disorders
Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141)
03/2003
03/20/2003US20030055250 Pteridine compounds for the treatment of psoriasis
03/20/2003US20030055248 Il-8 receptor antagonists
03/20/2003US20030055102 For therapy of allergic or inflammatory disorders of the eye and nose
03/20/2003US20030055098 Method of treatment
03/20/2003US20030055097 Indazolyl-substituted pyrroline compounds as kinase inhibitors
03/20/2003US20030055084 Pharmaceutical compounds and methods of use thereof
03/20/2003US20030055077 Method and compositions for the treatment of allergic conditions using pgd2 receptor antagonists
03/20/2003US20030055073 Remedies for sjoegren's syndrome
03/20/2003US20030055068 Pyrazole compounds useful as protein kinase inhibitors
03/20/2003US20030055054 CXCR3 antagonists
03/20/2003US20030055044 Administering pyrazole derivative for inhibiting GSK-3 or Aurora activity in a patient
03/20/2003US20030055032 For therapy or inhibiting the development of a pathology associated with peroxynitrite damage
03/20/2003US20030055024 Administering in divided doses an effective amount of a vascular damaging agent or a pharmaceutically acceptable salt thereof for production of a vascular damaging effect in a warm-blooded animal such as a human
03/20/2003US20030055003 Administering copper chelator and activated protein C (APC) or protein C or agent that increases the synthesis of protein C in the animal, or both, an activator of protein C for therapy
03/20/2003US20030054996 Contacting complex comprising a GRP94 protein with a binding agent that is immobilized to a solid phase support, to immobilize the complex to solid phase support; collecting the remaining sample; eluting the complex from solid phase support
03/20/2003US20030054990 Methods of using neural thread proteins to treat tumors and other conditions requiring the removal or destruction of cells
03/20/2003US20030054490 Isolated human phosphatase proteins, nucleic acid molecules encoding phosphatase proteins and uses thereof
03/20/2003US20030054488 Goodpasture antigen binding protein
03/20/2003US20030054409 Novel complex-forming proteins
03/20/2003US20030054365 MHC class II antigen presenting cells containing oligonucleotides which inhibit Ii protein expression
03/20/2003US20030054042 Stabilization of chemical compounds using nanoparticulate formulations
03/20/2003US20030054037 Pharmaceutical compositions of adsorbates of amorphous drug
03/20/2003US20030054013 Tuberculosis therapy; anticancer agents
03/20/2003US20030054010 Molecular antigen array
03/20/2003US20030054003 Antitumor agents, anticarcinogenic agents
03/20/2003US20030053987 Synthetic hepatitis c genes
03/20/2003US20030053984 Bimer or an oligomer of a dimer, trimer, quadromer or pentamer of recombinant fusion proteins
03/20/2003CA2461692A1 Use of a protein of the crmp family for treating diseases related to the immune system
03/20/2003CA2460331A1 Use of a protein for the production of a medicament for stimulating the innate non-specific immune system
03/20/2003CA2460269A1 Alphavirus replicon vector systems
03/20/2003CA2459890A1 Crystal structure of baff, and use thereof in drug design
03/20/2003CA2459882A1 Thiophenylthiopyrane dioxides as mmp or tnf-alpha inhibitors
03/20/2003CA2459769A1 Igf-1 as feline vaccine adjuvant, in particular against feline retroviruses
03/20/2003CA2459713A1 Compositions and methods for priming monocytic dendritic cells and t cells for th-1 response
03/20/2003CA2459560A1 Methods of kidney transplantation utilizing developing nephric tissue
03/20/2003CA2459515A1 Indole derivatives
03/20/2003CA2459310A1 Method and composition for treating immune complex associated disorders
03/20/2003CA2457092A1 Lactic acid bacteria comprising unmethylated cytosine-guanine dinucleotides for use in therapy
03/20/2003CA2451454A1 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
03/20/2003CA2451254A1 Novel proteins and nucleic acids encoding same
03/19/2003EP1293566A1 A soluble toll-like receptor
03/19/2003EP1293201A2 Use of aminoadamantane compounds as immunoregulators
03/19/2003EP1292694A2 A recombinant non-replicating virus expressing gm-csf and uses thereof to enhance immune responses
03/19/2003EP1292687A2 Regulated antigen delivery system (rads) involving bacteria
03/19/2003EP1292685A2 Human lyases
03/19/2003EP1292679A1 A g-protein coupled receptor
03/19/2003EP1292678A2 G-protein coupled receptors
03/19/2003EP1292671A1 Method for obtaining characterised muscle-derived cell populations and uses
03/19/2003EP1292621A1 Compositions and methods for the endocytic presentation of immunosuppressive factors
03/19/2003EP1292620A2 Nuclear hormone receptor
03/19/2003EP1292619A2 B7-related nucleic acids and polypeptides and their uses for immunomodulation
03/19/2003EP1292605A2 Antisense modulation of inhibitor of dna binding-1 expression
03/19/2003EP1292604A1 2-aminocarbonyl-9h-purine derivatives
03/19/2003EP1292596A1 1,3,8-triaza-spiro[4,5]decan-4-one derivatives as neurokinin receptor antagonists
03/19/2003EP1292576A1 Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
03/19/2003EP1292333A1 Adjuvant composition comprising fha protein or fragment of fha protein in free form
03/19/2003EP1292332A2 Adjuvants and processes to induce a specific type of immune response
03/19/2003EP1292331A2 Immunostimulatory rna/dna hybrid molecules
03/19/2003EP1292330A1 Immunostimulating properties of a fragment of tgf- beta
03/19/2003EP1292329A1 Manipulation of negative stranded rna viruses by rearrangement of their genes and uses thereof
03/19/2003EP1292322A1 Immunosuppressor agent derived from morbillivirus
03/19/2003EP1292321A1 Method to increase class i presentation of exogenous antigens by human dendritic cells
03/19/2003EP1292284A2 Encapsulation of polynucleotides and drugs into targeted liposomes
03/19/2003EP1278528A4 Nucleoside analogs with carboxamidine-modified bicyclic base
03/19/2003EP1257281A4 Nucleoside analogs with carboxamidine modified monocyclic base
03/19/2003EP1178984B1 1-trifluoromethyl-4-hydroxy-7-piperidinyl-aminomethylchroman derivatives
03/19/2003EP1102579B1 Medicinal aerosol formulations
03/19/2003EP1080069B1 Anthranilic acid derivatives as inhibitors of the cgmp-phosphodiesterase
03/19/2003EP1011686A4 Modulation of human mast cell activation
03/19/2003EP0944636B1 PHENYL GLYOXAMIDES AS sPLA2 INHIBITORS
03/19/2003EP0900203B1 Quinoline derivatives, processes for their preparation, and their use as medicaments
03/19/2003EP0876482B1 Il-13 receptor polypeptide
03/19/2003EP0874635B1 Nonimmunogenic platelet and red blood cell compositions
03/19/2003EP0871490B1 Branched hydrazone linkers
03/19/2003EP0745094B1 Superagonists and antagonists of human il-6, and method for their selection
03/19/2003EP0736093B1 ANTISENSE NUCLEIC ACIDS FOR THE PREVENTION AND TREATMENT OF DISORDERS IN WHICH EXPRESSION OF c-erbB-2 PLAYS A ROLL
03/19/2003EP0722463B1 Methods and composition for the modulation of host immune response to allergens
03/19/2003EP0667902B1 Cdr grafted humanised chimeric t-cell antibodies
03/19/2003EP0556333B1 Avirulent salmonella microbes comprising a mutation in the cdt gene and uses therefor
03/19/2003EP0463101B2 Vaccination and methods against diseases resulting from pathogenic responses by specific t cell populations
03/19/2003CN1404482A Pteridine compounds for the treatment of psoriasis
03/19/2003CN1404481A Nicotinamide benzofused-heterocyclyl derivatives useful as selective inhibitors of PDE4 isozymes
03/19/2003CN1404480A Pyrimidine carboxamides useful as inhibitors of PDE4 isozymes
03/19/2003CN1404479A Novel 1,3-dihydro-2H-indol-2-one derivatives their preparing method and the pharmceutical composition containing the same
03/19/2003CN1404470A 2-OXo-1-pyrrolidine derivatives, process for preparing them and their uses
03/19/2003CN1404469A 2-Oxo-1-pyrrolidine derivatives, processes for preparing them and their uses
03/19/2003CN1404468A Novel use of phenylheteroalkylamine derivatives
03/19/2003CN1404401A G-CSF conjugates
03/19/2003CN1404400A Use of IL-18 inhibitors
03/19/2003CN1404399A Novel non-antigenic mucosal adjuvant formulation for modulating the effects of substances, including vaccine antigens in contact with mucosal body surface
03/19/2003CN1404398A Improved DNA vaccines for production-type animals
03/19/2003CN1404391A Treating allergic and inflammatory conditions
03/19/2003CN1403147A Medicines composition for raising body's immunity and its prepn
03/19/2003CN1103229C Electuary for treating allergic respiratory system diseases
03/19/2003CN1103221C Medicine for treating HIV infections
03/18/2003US6534544 Methods of treatment with compounds having RARα receptor specific or selective activity
03/18/2003US6534521 Useful in the treatment of inflammation, atherosclerosis, restenosis, and immune disorders such as arthritis and transplant rejection
03/18/2003US6534518 Polysubstituted 6-phenylphenanthridines with PDE-IV inhibiting activity
03/18/2003US6534510 Anticoagulants
03/18/2003US6534499 For therapy of autoimmune disease
1 ... 734 735 736 737 738 739 740 741 742 743 744 745 746 747 748 749 750 751 752 753 754 ... 1172